Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza... see more

Recent & Breaking News (NDAQ:AZN)

Voluntis étend son partenariat avec AstraZeneca dans les thérapies digitales en oncologie

Business Wire August 30, 2018

Free Technical Briefing on Drug Makers Stocks -- GW Pharma, AbbVie, AstraZeneca, and Bristol-Myers Squibb

PR Newswire July 26, 2018

Immunomedics Announces Clinical Collaboration With AstraZeneca in First-Line Triple-Negative Breast and Urothelial Cancers

GlobeNewswire July 23, 2018

LYNPARZA® (olaparib) Significantly Delays Disease Progression in Phase III 1st-Line SOLO-1 Trial for Ovarian Cancer

Business Wire June 27, 2018

FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic Control with Additional Benefits Vs. Insulin Glargine in Patients with Type 2 Diabetes

Business Wire June 25, 2018

AstraZeneca to Share Latest Data from an Industry-Leading Portfolio That Aims to Advance Clinical Understanding of Diabetes and CV Risk Management at ADA 2018

Business Wire June 19, 2018

Seroquel Stepping Stone: How Luye Will Use Seroquel to Expand in Emerging Markets

PR Newswire June 6, 2018

LYNPARZA® (olaparib) in Combination with Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer

Business Wire June 4, 2018

Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting

Business Wire June 2, 2018

IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer

Business Wire May 25, 2018

AstraZeneca Heads to 2018 ASCO Annual Meeting with Its Diversified Oncology Portfolio and Next-Generation Pipeline

Business Wire May 24, 2018

Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Benzinga.com  May 23, 2018

LOKELMATM Approved in the US for the Treatment of Adults with Hyperkalemia

Business Wire May 18, 2018

The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Benzinga.com  May 13, 2018

Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR

Business Wire April 15, 2018

Ionis and AstraZeneca Advance New Drug for NASH

PR Newswire April 9, 2018

US FDA Approves BYDUREON for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control

Business Wire April 3, 2018

US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia

Business Wire April 3, 2018

Report: Exploring Fundamental Drivers Behind Mobile TeleSystems OJSC, Scorpio Tankers, Magellan Midstream Partners, National Steel, AstraZeneca, and Alibaba Group Holding — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire March 27, 2018

AstraZeneca Presents New Data Evaluating Safety and Efficacy of FARXIGA in Patients with Type 2 Diabetes and Moderate Renal Impairment

Business Wire March 19, 2018